[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356226-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356226-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","low-ctdnep1-expression-predicts-poor-prognosis-and-is-associated-with-immune-modulation-in-pancreatic-cancer","Low CTDNEP1 Expression Predicts Poor Prognosis and Is Associated With Immune Modulation in Pancreatic Cancer","","Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal due to limited therapies, so identifying genes that shape tumor progression is critical. This study examined CTDNEP1 using multi-omics cohorts from TCGA and Pan-Cancer Atlas, combining Kaplan-Meier survival assessment with gene set enrichment (GO/KEGG) and immune infiltration analyses. CTDNEP1 was reduced in PDAC versus normal tissue, especially early-stage tumors, and low expression linked to poorer prognosis, mutation-associated driver events, and distinct immune and inflammatory pathway associations. Results support CTDNEP1 as a tumor suppressor and potential biomarker/therapeutic target.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/low-ctdnep1-expression-predicts-poor-prognosis-and-is-associated-with-immune-modulation-in-pancreatic-cancer/356226/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/low-ctdnep1-expression-predicts-poor-prognosis-and-is-associated-with-immune-modulation-in-pancreatic-cancer/356226.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main purpose of this study?","Question",{"text":63,"@type":64},"To investigate whether CTDNEP1 expression influences PDAC progression and clinical outcomes, and how it relates to biological pathways and the tumor immune microenvironment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What datasets and analyses were used to assess CTDNEP1?",{"text":68,"@type":64},"CTDNEP1 expression was analyzed using TCGA and Pan-Cancer Atlas, with Kaplan-Meier survival analysis. Gene ontology and KEGG enrichment explored linked biology, and immune infiltration analysis assessed immune microenvironment associations.",{"name":70,"@type":61,"acceptedAnswer":71},"How does CTDNEP1 expression relate to patient prognosis in PDAC?",{"text":72,"@type":64},"Low CTDNEP1 expression correlates with significantly poorer patient prognosis, particularly in stage II PDAC.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356226,1791181264,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","doi: 10.21873/cgp.20567  \nLow CTDNEP1 Expression Predicts Poor Prognosis and Is Associated With Immune Modulation in Pancreatic Cancer  \nMAYUKA NII and TADAYOSHI HAYATA  \nDepartment of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Science, Tokyo University of Science, Tokyo, Japan  \nAbstract  \nBackground/Aim: Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy due to limited therapeutic options. Identifying novel genes that influence its progression is critical. This study aimed to investigate the role ofCTDNEP1, a phosphatase-encoding gene, in PDAC using multi-omics data from The Cancer Genome Atlas (TCGA) .  \nMaterials and Methods: We analyzed CTDNEP1 expression in PDAC using the TCGA and Pan-Cancer Atlas datasets. Kaplan-Meier survival analysis was performed to assess the association between CTDNEP1 expression and patient prognosis. Gene Ontology (GO) and KEGG pathway enrichment analyses were conducted to explore the biological processes linked to CTDNEP1 expression. Finally, we examined the relationship between CTDNEP1 expression and the tumor immune microenvironment using immune infiltration analysis.  \nResults: CTDNEP1 expression was found to be significantly lower in PDAC tissues compared to normal tissues, especially in early-stage tumors. This downregulation was associated with mutations in key driver genes, including KRAS, CDKN2A, TP53, and SMAD4. Importantly, low CTDNEP1 expression correlated with significantly poorer patient prognosis, particularly in stage II PDAC. Functional enrichment analysis revealed that low CTDNEP1 expression is associated with macroautophagy, protein degradation, and immune/inflammatory pathways, while high expression is linked to mitochondrial function and metabolic activity. Furthermore, CTDNEP1 expression showed a positive correlation with immune cell infiltration.  \nConclusion: CTDNEP1 functions as a tumor suppressor in PDAC, influencing tumor progression, immune response, and patient survival. Future studies should investigate the detailed regulatory mechanisms ofCTDNEP1 and explore its potential as a therapeutic target or biomarker for PDAC.  \nKeywords: Pancreatic ductal adenocarcinoma (PDAC), CTDNEP1, prognosis, tumor suppressor gene, immune infiltration.  \ne✉-mail:Phharmaceuticaayata tadayolsSchiienmpceh@, TorksyotusUancivejprsity of Science, 6-3-1 Niijuku, Katsushika, Tokyo 125-8585, Japan. Tel: +81 358761745,  \nTadayoshi Hayata, Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences and Faculty of  \nReceived September 16, 2025 | Revised October 21, 2025 | Accepted November 3, 2025  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n©2026 The Author(s) . Anticancer Research is published by the International Institute of Anticancer Research.  \nIntroduction  \nPancreatic cancer, especially pancreatic ductal adenocarcinoma (PDAC), is a devastating malignancy characterized by aggressive local invasion and early metastasis (1, 2) . It is among the deadliest cancers, with incidence and mortality rates steadily rising. A significant clinical challenge lies in the late-stage diagnosis of most patients, often duetothe absence of early symptoms and the lack of reliable biomarkers. Therefore, identifying novel genes implicated in PDAC progression is a critical unmet need.  \nCTD nuclear membrane phosphatase 1 (CTDNEP1) is a gene encoding a phosphatase (3) . Studies in mice have demonstrated that Ctdnep1 deficiency leads to enhanced BMP and TGF-β signaling, resulting in renal failure (4), ovarian hemorrhage (5), and delayed bone formation (6) . Furthermore, emerging evidence suggests a link between CTDNEP1deficiencyandthedevelopmentofmedulloblastoma, a pediatric brain tumor, hinting at a potential tumor suppressor role (7-9) . However, the role o","cbCain0EPHHmi7FW","https://ap.wps.com/l/cbCain0EPHHmi7FW","pdf",4303545,"English","# Abstract\n# Introduction\n# Materials and Methods","[{\"question\":\"What was the main purpose of this study?\",\"answer\":\"To investigate whether CTDNEP1 expression influences PDAC progression and clinical outcomes, and how it relates to biological pathways and the tumor immune microenvironment.\"},{\"question\":\"What datasets and analyses were used to assess CTDNEP1?\",\"answer\":\"CTDNEP1 expression was analyzed using TCGA and Pan-Cancer Atlas, with Kaplan-Meier survival analysis. Gene ontology and KEGG enrichment explored linked biology, and immune infiltration analysis assessed immune microenvironment associations.\"},{\"question\":\"How does CTDNEP1 expression relate to patient prognosis in PDAC?\",\"answer\":\"Low CTDNEP1 expression correlates with significantly poorer patient prognosis, particularly in stage II PDAC.\"}]","Low CTDNEP1 Expression Predicts Poor Prognosis and Is Associated With Immune Modulation in Pancreatic Cancer | PDF",1790124178,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a634f2d4bb7ecc536bfd2ed3d20075cb.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0fef5ea057ab81193535c737d73baa0d.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d7ad80c383e5f0531ad796029953d84.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2cd24861ac9dcd8245d57a1c94573f19.webp",980,1306]